908 Devices

MASS

Market cap $288M

908 Devices (MASS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

BURLINGTON, Mass.--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, announced that on June 1, 2026, the Compensation Committee of its Board of Directors granted options to four new non-executive employees to purchase an aggregate of 179,912 shares of 908 Devices' common stock. The options were granted as a material inducement to employment with 908 D.

BURLINGTON, Mass.--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, announced that CEO and Co-founder Kevin J. Knopp and CFO Joe Griffith will present and host investor meetings at the 16th Annual East Coast IDEAS Conference on Wednesday, June 10, 2026. The Company presentation is scheduled to begin at 8:35 a.m. Eastern Time. The presentation is webc.

908 Devices (MASS) delivered strong Q1 results, raising full-year revenue guidance after a strategic acquisition in narcotics detection. Adjusted gross margins improved nearly three percentage points to 57%, and operating cash flow turned positive. The company has a solid balance sheet with nearly $100 million in cash post-acquisition and is debt free, while trading at a reasonable valuation.

908 Devices Inc. (MASS) Q1 2026 Earnings Call Transcript

908 Devices Inc. (MASS) came out with a quarterly loss of $0.15 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.22 per share a year ago.

BURLINGTON, Mass.--(BUSINESS WIRE)-- #ChemicalID--908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, today reported financial results for the quarter ended March 31, 2026. “We delivered a strong start to 2026, achieving 14% revenue growth and meaningful margin expansion,” said Kevin J. Knopp, CEO and Co-founder. “We are also excited to announce the acquisition of NIRLAB AG, a strate.

BURLINGTON, Mass.--(BUSINESS WIRE)-- #LawEnforcement--908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld devices for chemical analysis, announces that it has completed the acquisition of NIRLAB AG, a privately held company based in Lausanne, Switzerland. The company delivers AI-powered, cloud-connected near-infrared (NIR) spectroscopy to perform handheld chemical analysis of narcotics in seconds. This acquisition expands 908 Devices' analytical portfolio and strengthens its leadership in narcot.

BURLINGTON, Mass.--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, announced it will report financial results for the first quarter 2026 before market open on Wednesday, May 6, 2026. Company management will webcast a corresponding conference call beginning at 8:30 a.m. Eastern Time. Live audio of the webcast will be available on the “Investors” sect.

BURLINGTON, Mass.--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld devices for chemical analysis, announces the appointment of Kola Otitoju as its Chief Business & Strategy Officer, a newly created executive position. Mr. Otitoju will oversee product and corporate strategy, business development, mergers and acquisitions, and partnership initiatives as 908 Devices expands its market presence across public health, safety, and defense-tech applications. Mr.